287 related articles for article (PubMed ID: 9119123)
1. Process changes and their effect on process evaluation for viral clearance.
Marcus-Sekura C
Dev Biol Stand; 1996; 88():125-30. PubMed ID: 9119123
[TBL] [Abstract][Full Text] [Related]
2. Considerations in performing virus spiking experiments and process validation studies.
Darling AJ
Dev Biol Stand; 1993; 81():221-9. PubMed ID: 8174806
[TBL] [Abstract][Full Text] [Related]
3. Current issues in viral assays and viral clearance evaluation.
Lubiniecki AS
Dev Biol Stand; 1996; 88():9-11. PubMed ID: 9119167
[TBL] [Abstract][Full Text] [Related]
4. Transmissible spongiform encephalopathies (TSE): minimizing the risk of transmission by biological/biopharmaceutical products: an industry perspective.
Kozak RW; Golker CF; Stadler P
Dev Biol Stand; 1996; 88():257-64. PubMed ID: 9119148
[TBL] [Abstract][Full Text] [Related]
5. Strategies for viral removal and inactivation.
Burstyn DG; Hageman TC
Dev Biol Stand; 1996; 88():73-9. PubMed ID: 9119165
[TBL] [Abstract][Full Text] [Related]
6. Process scale considerations in evaluation studies and scale-up.
Walter JK; Werz W; Berthold W
Dev Biol Stand; 1996; 88():99-108. PubMed ID: 9119169
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of anti-viral filters.
Hughes B; Bradburne A; Sheppard A; Young D
Dev Biol Stand; 1996; 88():91-8. PubMed ID: 9119168
[TBL] [Abstract][Full Text] [Related]
8. Viral safety and clearance evaluation--implications for process change and comparability.
Dinowitz M
Dev Biol (Basel); 2002; 109():121-6. PubMed ID: 12434921
[TBL] [Abstract][Full Text] [Related]
9. Validation of removal of human retroviruses.
Marcus-Sekura CJ
Dev Biol Stand; 1991; 75():133-43. PubMed ID: 1794615
[TBL] [Abstract][Full Text] [Related]
10. Issues related to harmonization of testing requirements for viral safety.
Hayakawa T
Dev Biol Stand; 1996; 88():15-8. PubMed ID: 9119129
[TBL] [Abstract][Full Text] [Related]
11. Improvement of virus safety of an antihemophilc factor IX by virus filtration process.
Kim IS; Choi YW; Kang Y; Sung HM; Sohn KW; Kim YS
J Microbiol Biotechnol; 2008 Jul; 18(7):1317-25. PubMed ID: 18667862
[TBL] [Abstract][Full Text] [Related]
12. Viral validation design of a manufacturing process.
Larzul D
Dev Biol Stand; 1999; 99():139-50. PubMed ID: 10404885
[TBL] [Abstract][Full Text] [Related]
13. Validation of purification procedures for removing and/or inactivating viruses in biologicals: points to consider.
Vicari G
Dev Biol Stand; 1991; 75():227-32. PubMed ID: 1794625
[TBL] [Abstract][Full Text] [Related]
14. Risk reduction in biotherapeutic products.
Ill CR; Dehghani H
Curr Opin Drug Discov Devel; 2009 Mar; 12(2):296-304. PubMed ID: 19333875
[TBL] [Abstract][Full Text] [Related]
15. Changes in biological source material.
Robertson JS
Biologicals; 2006 Mar; 34(1):61-3. PubMed ID: 16330224
[TBL] [Abstract][Full Text] [Related]
16. A comparison of methods for the estimation of retroviral burden.
Bierley ST; Raineri R; Poiley JA; Morgan EM
Dev Biol Stand; 1996; 88():163-5. PubMed ID: 9119132
[TBL] [Abstract][Full Text] [Related]
17. Analysis of risk to biomedical products developed from animal sources (with special emphasis on the spongiform encephalopathy agents, scrapie and BSE).
Rohwer RG
Dev Biol Stand; 1996; 88():247-56. PubMed ID: 9119146
[TBL] [Abstract][Full Text] [Related]
18. Use of bacteriophages as surrogates for mammalian viruses.
McAlister M; Aranha H; Larson R
Dev Biol (Basel); 2004; 118():89-98. PubMed ID: 15645677
[TBL] [Abstract][Full Text] [Related]
19. Anion exchange chromatography provides a robust, predictable process to ensure viral safety of biotechnology products.
Strauss DM; Gorrell J; Plancarte M; Blank GS; Chen Q; Yang B
Biotechnol Bioeng; 2009 Jan; 102(1):168-75. PubMed ID: 18683259
[TBL] [Abstract][Full Text] [Related]
20. [Viral safety concept: application to blood and blood products].
Trouvin JH
Rev Prat; 2005 Nov; 55(18):2033-8. PubMed ID: 16419908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
